EULAR 2026 | GRANT FOR PUBLISHING LICENCE

Licence Agreement between the Author(s) of the Abstract and the European Alliance of Associations for Rheumatology (EULAR)

Author’s Licence Grant for the Review and Evaluation

Each author hereby grants to EULAR the non-exclusive right to use, reproduce and share with third parties (such as EULAR’s volunteers or EULAR’s providers) the Abstract for the purpose of reviewing and evaluating the Abstract and for the purpose of checking compliance with law, this Agreement and EULAR policies, such as checking for plagiarism and “salami slicing”.

Author’s Licence Grant in the Accepted Abstract

Each author hereby grants to EULAR the following rights, together with the right to sublicence to its publishers, effective from the date on which the Abstract is accepted:

1. the perpetual, non-exclusive right to publish, reproduce, display, film, present, reformat, adapt, distribute and otherwise use the Abstract, or any part of the Abstract, for any purpose, in any medium or format (whether now known or later developed), and to prepare derivative works, in any form, in all languages, throughout the world.
2. the perpetual and exclusive right to sublicense the Abstract to third parties for commercial purposes;
3. the right to enforce the rights granted herein against third parties.

In addition, each author grants to EULAR the right to apply the Creative Commons Attribution-Non-commercial Works 4.0 International License (“the CC BY-NC License”) to the Abstract where the Abstract is published during the EULAR Congress, in the EULAR’s Websites, in EULAR’s Mobile App, in the Annals of Rheumatic Diseases (ARD) and/or EULAR’s publisher’s platforms on an Open Access basis. Full details of the CC BY-NC License are available at https://creativecommons.org.

Author’s right to use the Abstract

Subject to the embargo period restrictions, the exclusive licence grant and the other terms stated above, each author retains the right to use the Abstract for their own commercial and non-commercial purposes, as well as to create derivative works, without having to seek EULAR’s permission nor having to grant any payment to EULAR. Each author shall, in connection with their use of the Abstract, acknowledge and attribute the original publication of the Abstract by inserting the following wording: “This Abstract has been accepted for publication by the European Alliance of Associations for Rheumatology (EULAR). The copyedited version is available online at: www.ard.eular.org”.

Each author understands that the exclusive licence granted above does not allow them to licence the Abstract, or part of the Abstract, to a third party for commercial purposes. Each author agrees to promptly refer any third-party requests for a licence for commercial purposes to Elsevier B.V. (www.elsevier.com/permissions).

Author’s Consent in the Recording

Each author hereby consents to the Recording. Each author further agrees that EULAR may:

1. publish, reproduce, display, reformat, adapt, distribute and otherwise use the Recording, or any part of the Recording, for any purpose, in any medium or format (whether now known or later developed), and prepare derivative works, in any form, in all languages, throughout the world;
2. grant licences to third parties to use the Recording for commercial and non-commercial purposes.

Each author takes note that EULAR may apply the Creative Commons Attribution-Non-commercial Works 4.0 International License (“the CC BY-NC License”) to the Recording where the Recording is published on the EULAR Congress, the EULAR’s Websites, EULAR’s Mobile App. Full details of the CC BY-NC License are available at https://creativecommons.org.

Each author understands that EULAR will thereby process their personal data worldwide and that their data will be processed in accordance with EULAR’s privacy policy.

No compensation

Neither party shall owe any compensation or remuneration or reimbursement of any expense to the other Party under this Agreement.

Author’s Representations

Each author hereby represents that

1. the Abstract submitted is original and has been written by the stated author(s);
2. neither author(s) is subject to any law or bound to any agreement, including an agreement with an employer, research institution or a provider of a grant or bursary, that would prevent them to enter into this Agreement and/or to grant the rights as foreseen under this Agreement;
3. the person presenting the Abstract is entitled to present the Abstract at the EULAR Congress and that they will present the Abstract in person. If, unexpectedly, the presenting author is unable to attend the Congress, they will assign a co-author to present the Abstract onsite;
4. the Abstract, and/or the Abstract presentation, and/or the scientific information relating to the Abstract, and/or the scientific information relating to the Abstract, and/or research data do not infringe any applicable law, and has appropriate approval under local, ethical and animal experimentation rules;
5. the Abstract, and/or the Abstract presentation, and/or the scientific information relating to the Abstract, and/or research data do not infringe any third-party rights such as intellectual property rights (such as patents, trademarks, copyrights, etc.) or privacy rights or personality rights;
6. the Abstract, and/or the Abstract presentation, and/or the scientific information relating to the Abstract, and/or research data do not contain any libelous or other unlawful matter;
7. if any personal details or images of patients, research subjects or other individuals have been used, all consents required by applicable law have been obtained and evidence of such consents has been retained, and the author(s) has/have complied with EULAR and/or EULAR’s publisher’s policies relating to the use of such materials. See http://www.elsevier.com/patientphotographs for further information;
8. no author is an identified as a Specially Designated National (“SDN”) and if any of the authors reside in Russia or Belarus, has co-authored the Abstract as part of an international collaborative research, the Abstract has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution;
9. no author works for or has received funds from a Russian or Belarussian company (in particular pharmaceutical, biotech, or other similar industry bodies, etc.) and no presenting author resides in Russia or Belarus.

Governing Law and Jurisdiction

This Agreement is governed by and construed in accordance with the laws of Switzerland, without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the ordinary courts at the registered seat of EULAR.

The Terms of EULAR Website apply analogously to the use of this website (https://www.eular.org/disclaimer).